Checkpoint / Bayer HealthCare AG. / Merck KGAA / Sponsor Breakdown 30 Academic/Cancer Group / Medivation Inc. / Pfizer Inc. / CoStim Pharmaceuticals Inc. And Pfizer Inc. / Adaptimmune Ltd. / MedImmune LLC / Genentech Inc. / MacroGenics Inc. / AstraZeneca PLC / Sutro Biopharma Inc. / Micromet Inc. / Informa Business Information Inc. / Celgene Corp. / Facet Biotech Corp. / Merck & Co. Inc. / Amgen Inc. / AbbVie Inc. / Compugen Ltd. / Bristol-Myers Squibb Co. / Bionest Partners / Abbott Laboratories Inc. / Novartis AG / Celldex Therapeutics Inc. / Kite Pharma Inc. / Teva Pharmaceutical Industries Ltd. / Medarex Inc. / Cellectis SA / Immunocore Ltd. / CureTech Ltd. / GlaxoSmithKline PLC / Servier SA. / /
Country
Japan / /
Currency
USD / / /
Event
FDA Phase / Business Partnership / M&A / /
Facility
University of Pennsylvania CAR-T / CD27 checkpoint / ACCESS THESE ARTICLES AT OUR ONLINE STORE / Health’s National Cancer Institute / University of Pennsylvania / /
IndustryTerm
cancer therapy / other cancer therapies / treatment of cancer / immune systems / ONLINE STORE / /
MedicalCondition
tumor’s inflammatory state / constant inflammatory state / bladder cancer / melanoma / non-small-cell lung cancer / refractory acute lymphocytic leukemia / orphan disease / leukemia / tumor / cancer / tumors / NSCLC / several solid tumors / diseases / well-defined and important tumor / Merkel cell carcinoma / several tumors / head and neck cancer / renal cell carcinoma / Coalesce Around Promising CAR-T Space In Cancer / cancers / Mutated melanoma / hematologic malignancies / /
National Institutes of Health’s National Cancer Institute / FDA / University of Pennsylvania CAR-T / the University of Pennsylvania / /
Person
David Chang / Big Pharma / Daniel Afar / Jamie Foley / Jim Allison / Tibor Keler / Peter Sandor / OLIVIER LESUEUR / MARK RATNER / André Choulika / Trevor Hallam / al- BIOPHARMA STRATEGIES AMGEN GETS / RACHEL LAING / Pascal Touchon / Axel Hoos / John Lin / /
Position
EVP and chief / freelance writer / head of development / chief scientific officer / CEO / entific officer / managing director / Major / VP / immunology / VP / global marketing and therapeutic area head / VP / business development and scientific cooperation / manager / VP / oncology R&D / chief medical officer / drug discovery specialist / marketing and therapeutic area head for oncology / head of development for Biotherapeutics division / /
Product
Xtandi / Sprycel / PD-1 / Keytruda / MPDL3280A / Abbvie drug / Japan / PD-1s / CD19 / /
ProvinceOrState
Pennsylvania / /
PublishedMedium
THE BUSINESS / /
Technology
radiation / allogeneic CAR-T technology / drug discovery / chemotherapy / treating cancer / BiTE technology / ADC / cell receptors / antibodies / drug development / /
Immunotherapy: Big Pharma’s Seductive Embrace The advent of the first wave of checkpoint inhibitors has the oncology community believing that immunotherapy will be foundational, in the same way that combination chemoth